Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
Publication date: Available online 4 February 2020Source: Seminars in Cancer BiologyAuthor(s): Thomas Efferth, Franz OeschAbstractThe oleogum resins of Boswellia species known as frankincense have been used for ages in traditional medicine in India, China and the Arabian world independent of its use for cultural and religious rituals in Europe. During the past two decades, scientific investigations provided mounting evidence for the therapeutic potential of frankincense. We conducted a systematic review on the anti-inflammatory and anti-cancer activities of Boswellia species and their chemical ingredients (e.g. 3-O-acetyl-11-keto-β boswellic acid, α- and β-boswellic acids, 11-keto-β-boswellic acid and other boswellic acids, lupeolic acids, incensole, cembrenes, triterpenediol, tirucallic acids, and olibanumols). Frankincense acts by multiple mechanisms, e.g. by the inhibition of leukotriene synthesis, of cyclooxygenase 1/2 and 5-lipoxygenase, of oxidative stress, and by regulation of immune cells from the innate and acquired immune systems. Furthermore, frankincense modulates signaling transduction responsible for cell cycle arrest and inhibition of proliferation, angiogenesis, invasion and metastasis. Clinical trials showed the efficacy of frankincense and its phytochemicals against osteoarthritis, multiple sclerosis, asthma, psoriasis and erythematous eczema, plaque-induced gingivitis and pain. Frankincense revealed beneficial effects towards brain tumo...
Publication date: Available online 28 March 2020Source: Academic RadiologyAuthor(s): Stanzione Arnaldo, Renato Cuocolo, Del Grosso Renata, Nardiello Anna, Romeo Valeria, Travaglino Antonio, Raffone Antonio, Bifulco Giuseppe, Zullo Fulvio, Insabato Luigi, Maurea Simone, Pier Paolo Mainenti
Authors: Wu G, Chen X, Cui N, He Y, Fan J, Yan D, Zhu X, Zhu X Abstract Background: Cholestasis is a common but serious clinical condition in preterm neonates. The current management for preterm neonatal cholestasis has limitations. The aim of this study was to determine effects of Bifidobacterium supplementation on the prevention and alleviation of cholestasis in preterm infants with very low birth weight. Methods: Preterm neonates with very low birth weight were enrolled in the Children's Hospital of Soochow University between December 2012 and December 2017. The patients were randomly assigned into Bifidobac...
Authors: Li W, Zhou Y, Shang C, Sang H, Zhu H Abstract Background: Proton pump inhibitor (PPI) and other acid-suppressing drugs are widely used in the treatment of gastrointestinal ulcer, upper gastrointestinal bleeding, gastritis, and gastric cancer (GC). About 80% of GC patients receive acid suppression treatment. PPI suppresses the production of gastric acid by inhibiting the function of H+/K+-ATPase in gastric parietal cells and raises the pH value to achieve therapeutic purposes. Some studies have found that PPI had a certain antitumor effect in the proliferation and apoptosis of tumor cells. But the effects o...
Publication date: Available online 27 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Srinivasa R. Rao, Nasullah K. Alham, Elysia Upton, Stacey McIntyre, Richard J. Bryant, Lucia Cerundolo, Emma Bowes, Stephanie Jones, Molly Browne, Ian Mills, Alastair Lamb, Ian Tomlinson, David Wedge, Lisa Browning, Korsuk Sirinukunwattana, Claire Palles, Freddie C. Hamdy, Jens Rittscher, Clare Verrill
Publication date: Available online 13 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Riccardo Giannini, Gemma Zucchelli, Mirella Giordano, Clara Ugolini, Roberto Moretto, Katarzyna Ambryszewska, Michele Leonardi, Elisa Sensi, Federica Morano, Filippo Pietrantonio, Chiara Cremolini, Alfredo Falcone, Gabriella Fontanini
Publication date: Available online 28 March 2020Source: Journal of OrthopaedicsAuthor(s): Fanjie Li, Yibin Du
Authors: Quaglino F, Manfrino L, Cestino L, Giusti M, Mazza E, Piovesan A, Palestini N, Lauro C, Castellano E Abstract Parathyroid carcinoma (PC) is a rare disease responsible for about 1% of primary hyperparathyroidism (PHPT) cases. PC usually has an indolent course, tough to differentiate from the benign causes of PHPT, and the only certain diagnosis is histologic. The gold standard surgical treatment is the en bloc resection associated with the homolateral thyroid loboistmectomy. The aim of this study was to underline the main differences between PC and benign PHPT, along with gathering epidemiological knowledge...
Publication date: Available online 27 March 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Gavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, Michael Levy, Emmanuelle Waubant, Julian Gold
Publication date: Available online 27 March 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Christopher H. Hawkes, Gavin Giovannoni, Michael Levy, Jeanette Lechner-Scott, Emmanuelle Waubant
Publication date: Available online 27 March 2020Source: Brain, Behavior, and ImmunityAuthor(s): Mpumelelo Ntogwa, Satoshi Imai, Ren Hiraiwa, Madoka Koyanagi, Mayuna Matsumoto, Takashi Ogihara, Shunsaku Nakagawa, Tomohiro Omura, Atsushi Yonezawa, Takayuki Nakagawa, Kazuo Matsubara
More News: Asthma | Biology | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | China Health | Clinical Trials | Eczema | Gingivitis | Glioma | India Health | Middle East Health | Multiple Sclerosis | Neurology | Osteoarthritis | Pain | Pain Management | Psoriasis | Toxicology